An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) issued inducement equity awards to Robert Claypoole as President and CEO, consisting of 375,000 restricted share units and options to purchase 850,000 shares of the Company's Class A common stock. The awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to continued employment. The exercise price for the options is $4.89. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
None.
Negative
None.
DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.
The awards consist of 375,000 restricted share units and options to purchase 850,000 shares of the Company’s Class A common stock. Both awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to Mr. Claypoole’s continued employment with the Company through each applicable vesting date. The exercise price for the options is $4.89.
The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
About Bioventus Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
What type of awards were issued to Robert Claypoole?
Robert Claypoole received 375,000 restricted share units and options to purchase 850,000 shares of Bioventus Inc.'s Class A common stock.
How will the awards vest?
The awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to Mr. Claypoole’s continued employment with the Company through each applicable vesting date.
What is the exercise price for the options?
The exercise price for the options is $4.89.
What rule were the awards approved in accordance with?
The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat
